<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264234</url>
  </required_header>
  <id_info>
    <org_study_id>18-9.1/27</org_study_id>
    <nct_id>NCT04264234</nct_id>
  </id_info>
  <brief_title>Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria</brief_title>
  <official_title>Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta previa cases are one of the difficult groups of patients to manage in modern
      obstetrics. When the literature is evaluated extensively, no clear information can be seen
      especially in terms of hospitalization time. Inpatient follow-up of this patients has
      negative effects like hospital infections in terms of the patient, workload in terms of
      health personnel and financial losses in terms of the country's economy. Placenta previa
      cases are complicated patients in which generalizations cannot be easily performed and they
      should be monitored at third level hospitals. In addition, care should be personalized
      considering the many reasons. In this study, placenta previa cases will be followed up at
      28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this
      follow-up will continue until delivery. Thus, in this study, it was aimed to determine the
      parameters that would allow systematic personalization of health service in this particular
      patient group by making risk assessment of placenta previa cases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of placental invasion pathologies</measure>
    <time_frame>1 day</time_frame>
    <description>Placental invasion pathologies detected during delivery will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of preterm birth</measure>
    <time_frame>1 day</time_frame>
    <description>The relation between preterm birth and placental invasion pathologies will be assessed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Placenta Previa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vaginal Ultrasonography</intervention_name>
    <description>Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.</description>
    <arm_group_label>Placenta Previa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.</description>
    <arm_group_label>Placenta Previa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Monitoring of placenta previa

          -  To apply before the 28th week

          -  To have a low-risk second trimester screening test

          -  No malformation detected in the anomaly screening

        Exclusion Criteria:

          -  Multiple pregnancies

          -  Pregnancy complicated with preeclampsia

          -  Pregnancy complicated by gestational hypertension

          -  Pregnancy complicated by gestational diabetes mellitus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant participant</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabahattin a Arı, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ege University Hospital</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Sabahattin Anıl Arı</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>placenta previa</keyword>
  <keyword>placental invasion anomalies</keyword>
  <keyword>timing of the birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

